{"id":"93cb82fd-9fa8-40f5-931c-2d36a8689fb9","companyId":"bba39508-3e95-4e2f-b736-9bd5ff7e567b","modelName":"Dexter","slug":"distalmotion-dexter","description":"Distalmotion (founded 2012 in the Lausanne area of Switzerland as an EPFL spinout; private) makes Dexter, a hybrid laparoscopic surgical robot designed for cost-efficiency and operating-room integration that lets surgeons switch between robotic and manual laparoscopy within the same procedure. Dexter is a genuine master-controlled robotic manipulator that received its European CE mark in December 2020, with European market launch following in 2021, and then crossed the key US gating event with FDA De Novo marketing authorization in October 2024 for adult inguinal hernia repair, since expanded with two further US clearances covering cholecystectomy and gynecologic procedures including total benign hysterectomy. The company reports nearly 3,000 patients treated across Europe and the US, raised $150 million in November 2025 to accelerate US expansion, and positions Dexter for ambulatory surgical centers as a cost-efficiency play. The registry records it at commercial maturity, solidly past its gating events and in early US scale-up, with a teleoperated master-slave baseline and no shipped autonomy or AI-assist feature. One date-precision note: the CE mark is December 2020, while the 2021 figure sometimes cited refers to the European launch year. Exact installed-system and country counts are not verified for the private company, and the roughly 3,000-patients figure is company-sourced and plausible but not regulatory-audited.","formFactor":"surgical","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"notes":[{"label":"Verified","value":"Distalmotion (founded 2012, Lausanne/Ecublens Switzerland; EPFL spinout; private) makes Dexter, a master-controlled laparoscopic robotic manipulator. CE mark Dec 2020 (European launch followed 2021). FDA De Novo Oct 2024 for adult inguinal hernia repair (first US indication and the key gating event), then two more US clearances (cholecystectomy; gynecology incl. total benign hysterectomy). Raised $150M Nov 18 2025; named Chas McKhann Executive Chairman. Targets ASCs (ambulatory surgical centers) as a cost-efficiency play."},{"label":"Maturity = commercial","value":"CE-marked since 2020 with European market launch, US De Novo plus two follow-on clearances, ~3,000 patients treated, and a $150M growth round: solidly commercial, in early US scale-up. Teleop master-slave baseline; no shipped autonomy/AI-assist feature."},{"label":"Date precision (correction)","value":"CE mark is Dec 2020 (the 2021 figure sometimes cited is the European LAUNCH year, not the CE date)."},{"label":"Claimed but NOT verified","value":"Exact installed-system count and country count (private company); the ~3,000-patients figure is company-sourced (plausible, not regulatory-audited)."}],"products":"Dexter: a hybrid laparoscopic surgical robot designed for cost-efficiency and OR integration, letting surgeons switch between robotic and manual laparoscopy in the same procedure. CE mark Dec 2020; FDA De Novo Oct 2024 (inguinal hernia repair); two further US indications (cholecystectomy; gynecology incl. total benign hysterectomy).","formFactor":"surgical (hybrid laparoscopic teleoperated robot: switch between robotic and manual laparoscopy mid-procedure)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.biospace.com/distalmotion-dexter-fda-de-novo","title":"FDA grants De Novo marketing authorization for the Distalmotion Dexter robot (Oct 2024)","sourceName":"BioSpace"},{"url":"https://www.bioworld.com/articles/distalmotion-ce-mark-dexter","title":"Distalmotion wins CE mark for Dexter surgical robot (Dec 2020)","sourceName":"BioWorld"},{"url":"https://www.globenewswire.com/news-release/2025/11/18/distalmotion-150-million","title":"Distalmotion raises $150M to accelerate US expansion (Nov 18 2025)","sourceName":"Distalmotion (GlobeNewswire)"},{"url":"https://www.massdevice.com/distalmotion-dexter-fda-clearance/","title":"Distalmotion Dexter FDA clearances; ASC cost-efficiency positioning","sourceName":"MassDevice"}],"aliases":["Dexter","Distalmotion Dexter"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T20:13:11.063Z","updatedAt":"2026-06-03T20:13:11.063Z","jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/distalmotion-dexter","url":"https://registry.deploy.report/models/distalmotion-dexter","name":"Dexter","alternateName":["Dexter","Distalmotion Dexter"],"description":"Distalmotion (founded 2012 in the Lausanne area of Switzerland as an EPFL spinout; private) makes Dexter, a hybrid laparoscopic surgical robot designed for cost-efficiency and operating-room integration that lets surgeons switch between robotic and manual laparoscopy within the same procedure. Dexter is a genuine master-controlled robotic manipulator that received its European CE mark in December 2020, with European market launch following in 2021, and then crossed the key US gating event with FDA De Novo marketing authorization in October 2024 for adult inguinal hernia repair, since expanded with two further US clearances covering cholecystectomy and gynecologic procedures including total benign hysterectomy. The company reports nearly 3,000 patients treated across Europe and the US, raised $150 million in November 2025 to accelerate US expansion, and positions Dexter for ambulatory surgical centers as a cost-efficiency play. The registry records it at commercial maturity, solidly past its gating events and in early US scale-up, with a teleoperated master-slave baseline and no shipped autonomy or AI-assist feature. One date-precision note: the CE mark is December 2020, while the 2021 figure sometimes cited refers to the European launch year. Exact installed-system and country counts are not verified for the private company, and the roughly 3,000-patients figure is company-sourced and plausible but not regulatory-audited.","identifier":"93cb82fd-9fa8-40f5-931c-2d36a8689fb9","category":"surgical","publisher":{"@id":"https://deploy.report/#organization"}}}